Double blind, placebo-controlled dose escalating, multiple dose study with two groups of 30 volunteers with type II diabetes to assess efficacy on glucose-profile, triglycerides and blood pressure and pharmacokinetics of two different doses of BLX-1002.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2011
At a glance
- Drugs BLX 1002 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 21 Jun 2011 New trial record